Cipla gets Form 483 for US Invagen plant.
Cipla's new U.S. plant received Form 483 just ahead of Deal
Last month India's Cipla announced it had struck a $550 million deal to buy its first U.S. property, InvaGen Pharmaceuticals, getting a 350,000-square-foot manufacturing facility and portfolio of drugs. What it left out of the announcement is that its first U.S. manufacturing operation came with some FDA concerns. The company received a Form 483 this spring for that plant, which the FDA did not post until two weeks after the deal was disclosed.
Cipla's new U.S. plant received Form 483 just ahead of Deal
Last month India's Cipla announced it had struck a $550 million deal to buy its first U.S. property, InvaGen Pharmaceuticals, getting a 350,000-square-foot manufacturing facility and portfolio of drugs. What it left out of the announcement is that its first U.S. manufacturing operation came with some FDA concerns. The company received a Form 483 this spring for that plant, which the FDA did not post until two weeks after the deal was disclosed.
No comments:
Post a Comment